Immune-mediated necrotizing myopathy

Immune-mediated necrotizing myopathy (IMNM) is a subgroup of the idiopathic inflammatory myopathies. There are three major subtypes based on autoantibodies, of which statin-associated autoimmune myopathy has been increasing in recent years. It is characterized by myopathological findings of multiple necrotic and regenerating fibers with little infiltration of inflammatory cells.[1][2][3]

  1. ^ Day, Jessica A.; Limaye, Vidya (2019). "Immune-mediated necrotising myopathy: A critical review of current concepts". Seminars in Arthritis and Rheumatism. 49 (3): 420–429. doi:10.1016/j.semarthrit.2019.04.002. ISSN 1532-866X. PMID 31109639.
  2. ^ Milone, Margherita (2017). "Diagnosis and Management of Immune-Mediated Myopathies". Mayo Clinic Proceedings. 92 (5): 826–837. doi:10.1016/j.mayocp.2016.12.025. ISSN 1942-5546. PMID 28473041. Retrieved 2025-04-11.
  3. ^ Anquetil, Céline; Boyer, Olivier; Wesner, Nadège; Benveniste, Olivier; Allenbach, Yves (2019). "Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy". Autoimmunity Reviews. 18 (3): 223–230. doi:10.1016/j.autrev.2018.09.008. ISSN 1873-0183. PMID 30639649.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.